INT90673

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2000
Last Reported 2010
Negated 3
Speculated 0
Reported most in Body
Documents 66
Total Number 78
Disease Relevance 69.71
Pain Relevance 12.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

protein modification process (LOX) extracellular space (LOX) oxidoreductase activity (LOX)
extracellular region (LOX) nucleus (LOX)
Anatomy Link Frequency
epithelium 5
blood vessel 4
macrophages 3
platelets 2
endothelia 2
LOX (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 766 99.84 Very High Very High Very High
Inflammation 687 99.46 Very High Very High Very High
Potency 25 99.28 Very High Very High Very High
licofelone 88 98.16 Very High Very High Very High
Inflammatory response 74 97.88 Very High Very High Very High
Analgesic 11 97.08 Very High Very High Very High
COX-2 inhibitor 305 96.68 Very High Very High Very High
COX2 21 96.56 Very High Very High Very High
acular 19 95.84 Very High Very High Very High
rheumatoid arthritis 31 91.64 High High
Disease Link Frequency Relevance Heat
Asthma 12 99.90 Very High Very High Very High
Renal Cancer 767 99.86 Very High Very High Very High
Reprotox - General 1 668 99.84 Very High Very High Very High
Hypersensitivity 12 99.64 Very High Very High Very High
Prostatic Intraepithelial Neoplasia 168 99.56 Very High Very High Very High
INFLAMMATION 929 99.46 Very High Very High Very High
Hemolysis 60 99.34 Very High Very High Very High
Malaria 300 99.28 Very High Very High Very High
Cancer 1086 99.08 Very High Very High Very High
Malignant Neoplastic Disease 63 99.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We have studied the conformational flexibility of three 5-keto-substituted 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofurans (DHDMBFs) which show dual cyclooxygenase (COX) and 5-lipoxygenase (LOX) inhibition and are potential candidates as antiinflammatory agents and analgesics.
Gene_expression (show) of LOX associated with inflammation and analgesic
1) Confidence 0.65 Published 2000 Journal Indian J. Biochem. Biophys. Section Abstract Doc Link 10983419 Disease Relevance 0.10 Pain Relevance 0.10
Here we describe the synthesis of COX/LOX inhibitors which additionally reduce the level of reactive oxygen species, such as hydroxyl radicals which are well known for supporting inflammation processes in Parkinson's disease, Alzheimer's disease and rheumatoid arthritis.
Gene_expression (synthesis) of LOX associated with inflammation, rheumatoid arthritis and disease
2) Confidence 0.65 Published 2008 Journal Eur J Med Chem Section Abstract Doc Link 17976864 Disease Relevance 0.56 Pain Relevance 0.23
COX-3 and 15-LOX were not expressed by human islets.
Neg (not) Gene_expression (expressed) of LOX
3) Confidence 0.63 Published 2007 Journal Diabetes Section Abstract Doc Link 17192482 Disease Relevance 0 Pain Relevance 0.07
Studies of LOX expression and activities in normal and cancerous lesions have
Gene_expression (expression) of LOX
4) Confidence 0.56 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.83 Pain Relevance 0.08
shown that 15-LOX-1 and 15-LOX-2 are usually expressed in normal tissues and
Gene_expression (expressed) of LOX
5) Confidence 0.56 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.84 Pain Relevance 0.08
Targeting overexpression of inducible enzymes, 5-LOX and COX-2 enzymes, as a
Gene_expression (overexpression) of LOX
6) Confidence 0.56 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.41 Pain Relevance 0.04
expressed enzymes, LOX-5, and COX-1 [40].
Gene_expression (expressed) of LOX
7) Confidence 0.56 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.64 Pain Relevance 0.25
shown that 15-LOX-1 and 15-LOX-2 are usually expressed in normal tissues and
Gene_expression (expressed) of LOX
8) Confidence 0.56 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.84 Pain Relevance 0.08
The roles played by arachidonic acid and its cyclooxygenase (COX)-generated and lipoxygenase (LOX)-generated metabolites have been studied using rodent islets and insulin-secreting cell lines, but very little is known about COX and LOX isoform expression and the effects of modulation of arachidonic acid generation and metabolism in human islets.
Gene_expression (expression) of LOX isoform
9) Confidence 0.49 Published 2007 Journal Diabetes Section Abstract Doc Link 17192482 Disease Relevance 0 Pain Relevance 0.05
benign lesions, whereas 5-LOX and 12-LOX are absent in normal epithelia and
Neg (absent) Gene_expression (absent) of LOX
10) Confidence 0.49 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.84 Pain Relevance 0.07
benign lesions, whereas 5-LOX and 12-LOX are absent in normal epithelia and
Neg (absent) Gene_expression (absent) of LOX
11) Confidence 0.49 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.84 Pain Relevance 0.07
pathway, may have great potency if involves inhibition of both the LOX and COX pathways and activation
Gene_expression (pathways) of LOX associated with potency
12) Confidence 0.49 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.97 Pain Relevance 0.13
pathway, a dual inhibition of both LOX and COX pathways has been proposed as a new approach to
Gene_expression (pathways) of LOX
13) Confidence 0.49 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.54 Pain Relevance 0.26
revealed that a dual inhibitor against LOX/COX is more effective than a
Gene_expression (/) of LOX
14) Confidence 0.49 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.97 Pain Relevance 0.16
New COX/LOX
Gene_expression (New) of LOX
15) Confidence 0.49 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.61 Pain Relevance 0.03
New COX/LOX
Gene_expression (/) of LOX
16) Confidence 0.49 Published 2008 Journal PPAR Research Section Body Doc Link PMC2652614 Disease Relevance 0.56 Pain Relevance 0.03
Consistent with our findings, Kelavkar and colleagues (2004) reported 15-LOX-1 is expressed in NP and increased in PC, especially high-grade PC.
Gene_expression (expressed) of LOX associated with reprotox - general 1
17) Confidence 0.47 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727910 Disease Relevance 1.84 Pain Relevance 0.15
We classified 3 categories (epithelium, blood vessel, a small quantity of stromal tissue) in RCC tissues and NK tissues, and examined the intensity of 5- and 12-LOX expressions. 5- and 12-LOX expressions were more intensive and extensive in all categories of RCC tissues as compared with NK tissues (Table 2).
Gene_expression (expressions) of LOX in blood vessel associated with renal cancer
18) Confidence 0.44 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994214 Disease Relevance 1.20 Pain Relevance 0.18
We have shown that 5- and 12-LOX expressions in RCC tissues were stronger than those in NK tissues by immunohistochemical staining (50 RCC and 10 NK tissues) and RT-PCR (Figure 2).
Gene_expression (expressions) of LOX associated with renal cancer
19) Confidence 0.44 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994214 Disease Relevance 1.26 Pain Relevance 0.25
There were significant differences only epithelium in RCC tissues, and 5- and 12-LOX expressions were stronger in high differentiation RCC (Matsuyama et al 2005).
Gene_expression (expressions) of LOX in epithelium associated with renal cancer
20) Confidence 0.44 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994214 Disease Relevance 1.34 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox